Monte Rosa Therapeutics reports Q1 results on May 8 with short sellers sitting at their most aggressive in months — and the stock priced well below where the Street sees fair value.
The short interest story here is the headline. Bears control roughly 27.6% of the free float, up sharply from 17–18% just six weeks ago in late March. That jump of nearly 10 percentage points in SI % FF happened almost entirely between early April and the week of April 13, when shorts added aggressively as the stock was trading in the mid-to-high teens. Since then the position has held firm, with barely any day-to-day movement — shorts have neither covered nor added materially heading into the print. Despite that scale of short interest, the borrow market tells a different story: cost to borrow is just 0.45% annualised, among the cheapest possible rates, and borrow availability remains ample. Shorts are in their position cheaply and comfortably.
Options traders are leaning the other way. The put/call ratio has collapsed to 0.12, well below its 20-day average of 0.25. That's near the bottom of its 52-week range (low was 0.049) and reflects a market stacked heavily with call exposure relative to puts. This creates a direct tension: a very large short position in the stock, but option flow dominated by calls. Either shorts are expressing their view through stock rather than puts, or call buyers are betting on a catalyst-driven squeeze into earnings. That divergence is worth watching closely on Friday morning.
The Street remains broadly constructive despite some target trimming earlier this year. After Guggenheim and Wells Fargo both lowered their price targets in mid-March — following a disappointing update — their ratings stayed positive (Buy and Overweight respectively). The consensus mean target of $32.17 implies more than 60% upside from the current $19.35. Piper Sandler is more bullish at $37. The bull case rests on the QuEEN platform and the MRT-8102 NEK7 MGD data; bears point to the competitive NLRP3 inhibitor landscape, reliance on collaboration revenue, and timeline risk around the GFORCE-2 study. The EPS momentum factor ranks in the 85th percentile — unusual for a pre-revenue biotech — suggesting estimate revisions have been running in the company's favour recently. Note that analyst data is dated to late March; no fresh changes have been recorded in the six weeks since.
Insider selling has been consistent and methodical. CEO Markus Warmuth sold shares on three separate occasions in 2026 — January, March, and again in late April — in transactions that appear to follow a structured plan rather than reflect conviction selling. The Chief Legal Officer and Chief Medical Officer also liquidated small tranches in the period. Net 90-day insider activity is a modest sale of roughly $1.1 million. These are not large positions relative to total shares outstanding, and the regularity of the cadence suggests pre-planned disposals rather than a directional signal. Among institutional holders, T. Rowe Price added 812,000 shares in Q1, BlackRock added 366,000, and Vanguard added 499,000 — all passive-or-growth managers increasing exposure alongside the rising short interest, which adds another layer of tension into the setup.
Post-earnings price reactions for GLUE have been mixed. The March 2026 event saw the stock fall 6.4% the following day and 4.2% over five days. A secondary update event in mid-March knocked another 3.6% on day one, extending to a 10% loss over the week. The prior November 2025 print, however, produced an 8% gain and a 10% five-day follow-through. That volatility pattern — large moves in either direction — combined with 27.6% of the float short and a call-skewed options market makes the May 8 release a highly binary event to watch.
See the live data behind this article on ORTEX.
Open GLUE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
